BMJ  2006;332:1344-1345 (10 June), doi:10.1136/bmj.332.7554.1344

Editorial

Switching statins

Using generic simvastatin as first line could save £2bn over five years in England

The first 150 words of the full text of this article appear below.

Statins are one of the great success stories of preventive medicine. Extensive evidence, excellent safety, and high efficacy have resulted in an exponential rise in prescriptions for statins, currently increasing at 30% a year in England. Statins represent the largest drug cost to the NHS (£738 million (1.1bn; $1.4bn) in 2004).¹

Around 85% of all statin prescriptions in England are for simvastatin and atorvastatin, in roughly equal proportions, usually at moderate or low doses (98% of simvastatin is prescribed at 40 mg, 85% of atorvastatin at 20 mg). In May 2003 the UK simvastatin patent expired and the cost reduced eightfold for the 40 mg dose and 20-fold for the 20 mg dose. The maximum price of simvastatin 40 mg is now up to six times cheaper than atorvastatin (£3.89, £18.03, and £24.64 respectively for simvastatin 40 mg, atorvastatin 10 mg and 20 mg),² and simvastatin 40 mg . . . [Full text of this article]

Department of Cardiology, Heart Hospital, UCL Hospitals NHS Foundation Trust, London W1G 8PH
(james.moon@uclh.nhs.uk)

Experimental Medicine and Toxicology, Imperial College London, London W12 0HS, UK.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

How much will Herceptin really cost?: The money is already there

Rubin Minhas
BMJ 2006 333: 1219. [Extract] [Full Text] [PDF]

How much will Herceptin really cost?: Summary of other responses

Birte Twisselmann
BMJ 2006 333: 1219-1220. [Extract] [Full Text] [PDF]

Hit parade
BMJ 2006 333: 308. [Extract] [Full Text]

Switching statins: Cost of simvastatin is overestimated

John S Ashcroft
BMJ 2006 332: 1512. [Extract] [Full Text]

Switching statins: NICE tool overestimates benefits of statins

D Graham Mackenzie
BMJ 2006 332: 1512-1513. [Extract] [Full Text]

Switching statins: How to do it without tears and to benefit the NHS

Thomas Lau
BMJ 2006 332: 1513. [Extract] [Full Text]

This article has been cited by other articles:

• Corp, E.V., Antoniou, S., Wright, P.G., Khachi, H., Vercaeren, S., Wald, D.S. (2009). Use and cost of branded and generic drugs in patients with coronary heart disease--results from a prospective survey of 1008 patients in two London hospitals. QJM 0: hcp127v1-hcp127 [Abstract] [Full text]  
• Gao, F., Linhartova, L., Johnston, A. McD., Thickett, D. R. (2008). Statins and sepsis. Br J Anaesth 100: 288-298 [Abstract] [Full text]  
• Siyambalapitiya, S., Bulugahapitiya, U., Sithole, J., Song, S., Fernando, D. J.S., Idris, I. (2007). Combining Population Health and Baseline Risk Strategy by Determining an Age Cutoff for Initiating Statins in Patients With Diabetes: A population-based study. Diabetes Care 30: 2025-2029 [Abstract] [Full text]  
• (2007). Which statin, what dose?. DTB 45: 33-37 [Abstract] [Full text]  
• Minhas, R., Moon, J. C (2007). The Office of Fair Trading report: a prescription for value-based drug pricing. JRSM 100: 216-218 [Full text]  
• Minhas, R. (2006). How much will Herceptin really cost?: The money is already there. BMJ 333: 1219-1219 [Full text]  
• (2006). Hit parade. BMJ 333: 308-308 [Full text]  
• Lau, T. (2006). Switching statins: How to do it without tears and to benefit the NHS.. BMJ 332: 1513-1513 [Full text]  
• Ashcroft, J. S (2006). Switching statins: Cost of simvastatin is overestimated.. BMJ 332: 1512-1512 [Full text]  
• Mackenzie, D G. (2006). Switching statins: NICE tool overestimates benefits of statins.. BMJ 332: 1512-1513 [Full text]  

Rapid Responses:

Read all Rapid Responses

A Four to Eight Fold Overestimate of Cost of Simvastatin

John S Ashcroft
bmj.com, 10 Jun 2006 [Full text]

Switching statins works with ‘an adequate dose’ but not ‘target-chasing’

Martin G Duerden
bmj.com, 12 Jun 2006 [Full text]

Patently absurd

Vadivelu Saravanan
bmj.com, 12 Jun 2006 [Full text]

The individual patient should not be forgotten

Gordon A A Ferns
bmj.com, 12 Jun 2006 [Full text]

NICE tool over-estimates benefits of statins

D Graham Mackenzie
bmj.com, 14 Jun 2006 [Full text]

Switching statins without tears and benefit the NHS

Thomas Lau
bmj.com, 14 Jun 2006 [Full text]

Statin Debate: Economics or Advertising

Tariq Hussain
bmj.com, 15 Jun 2006 [Full text]

Simva switching - slow and variable

Mark B Gregory
bmj.com, 15 Jun 2006 [Full text]

Switching Statins – Irony of evidence-based healthcare?

Shahirose Jessani, et al.
bmj.com, 16 Jun 2006 [Full text]

Other issues when switching Statins

J Mark Dinwoodie
bmj.com, 16 Jun 2006 [Full text]

Short term gains; long term costs

William D Strain
bmj.com, 16 Jun 2006 [Full text]

Switching Statins

Timothy J Cantor
bmj.com, 17 Jun 2006 [Full text]

Re: Switching Statins

Edward D Nicol
bmj.com, 19 Jun 2006 [Full text]

GP Targets

M G Bamber, et al.
bmj.com, 20 Jun 2006 [Full text]

The need to be clear about the affordability of JBS 2 'target chasing'

Christopher F Corfield, et al.
bmj.com, 21 Jun 2006 [Full text]

Simvastatin as first line statin

David Gill, et al.
bmj.com, 23 Jun 2006 [Full text]

Targets in secondary prevention

Paul Nicholls, et al.
bmj.com, 5 Jul 2006 [Full text]

Switching statins; side effects

Michael R Pokorny
bmj.com, 7 Sep 2006 [Full text]

Switching statins: an appropriate guideline for clinical practice?

Michele Cortellaro, et al.
bmj.com, 26 Oct 2006 [Full text]

The 3T Study

Mahmood Ahmad
bmj.com, 27 Oct 2006 [Full text]

Switching statins forgetting secondary prevention of cerebrovascular events and other important variables ?

Antonino Tuttolomondo, et al.
bmj.com, 4 Dec 2006 [Full text]

Switching statins: is it true evidence based medicine?

Francesco Cipollone
bmj.com, 5 Dec 2006 [Full text]

Response to prof. Cipollone: mortality versus 'event' based cardiology.

Eddie Vos, et al.
bmj.com, 7 Dec 2006 [Full text]

Online poll

Find out more >>